Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:44-50
Published online before print December 20, 2004, doi: 10.1161/01.CIR.0000151614.22282.F1
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/1/44    most recent
01.CIR.0000151614.22282.F1v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Inagaki, K.
Right arrow Articles by Mochly-Rosen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inagaki, K.
Right arrow Articles by Mochly-Rosen, D.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Ischemic biology - basic studies

(Circulation. 2005;111:44-50.)
© 2005 American Heart Association, Inc.


Coronary Heart Disease

Cardioprotection by {epsilon}-Protein Kinase C Activation From Ischemia

Continuous Delivery and Antiarrhythmic Effect of an {epsilon}-Protein Kinase C-Activating Peptide

Koichi Inagaki, MD, PhD*; Rebecca Begley, PhD*; Fumiaki Ikeno, MD; Daria Mochly-Rosen, PhD

From the Department of Molecular Pharmacology, Stanford University School of Medicine (K.I., R.B., D.M.-R.), and Department of Cardiovascular Medicine, Stanford University (F.I.), Stanford, Calif.

Correspondence to Daria Mochly-Rosen, Department of Molecular Pharmacology, 269 Campus Dr, 3145 CCSR, Stanford University School of Medicine, Stanford CA 94305-5174. E-mail mochly{at}stanford.edu

Received July 24, 2004; revision received September 10, 2004; accepted September 30, 2004.

Background— We previously showed that a selective activator peptide of {epsilon}-protein kinase C (PKC), {psi}{epsilon}RACK, conferred cardioprotection against ischemia-reperfusion when delivered ex vivo before the ischemic event. Here, we tested whether in vivo continuous systemic delivery of {psi}{epsilon}RACK confers sustained cardioprotection against ischemia-reperfusion in isolated mouse hearts and whether {psi}{epsilon}RACK treatment reduces infarct size or lethal arrhythmias in porcine hearts in vivo.

Methods and Results— After {psi}{epsilon}RACK was systemically administered in mice either acutely or continuously, hearts were subjected to ischemia-reperfusion in an isolated perfused model. Whereas {psi}{epsilon}RACK-induced cardioprotection lasted 1 hour after a single intraperitoneal injection, continuous treatment with {psi}{epsilon}RACK induced a sustained preconditioned state during the 10 days of delivery. There was no desensitization to the therapeutic effect, no downregulation of {epsilon}PKC, and no adverse effects after sustained {psi}{epsilon}RACK delivery. Porcine hearts were subjected to ischemia-reperfusion in vivo, and {psi}{epsilon}RACK was administered by intracoronary injection during the first 10 minutes of ischemia. {psi}{epsilon}RACK treatment reduced infarct size (34±2% versus 14±1%, control versus {psi}{epsilon}RACK) and resulted in fewer cases of ventricular fibrillation during ischemia-reperfusion (87.5% versus 50%, control versus {psi}{epsilon}RACK).

Conclusions— The {epsilon}PKC activator {psi}{epsilon}RACK induced cardioprotection both in vivo and ex vivo, reduced the incidence of lethal arrhythmia during ischemia-reperfusion, and did not cause desensitization or downregulation of {epsilon}PKC after sustained delivery. Thus, {psi}{epsilon}RACK may be useful for patients with ischemic heart disease. In addition, the {psi}{epsilon}RACK peptide should be a useful pharmacological agent for animal studies in which systemic and sustained modulation of {epsilon}PKC in vivo is needed.


Key Words: arrhythmia • ischemia • ischemic preconditioning • peptides • protein kinase C




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen
Protein kinase C in heart failure: a therapeutic target?
Cardiovasc Res, May 1, 2009; 82(2): 229 - 239.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Inagaki, T. Koyanagi, N. C. Berry, L. Sun, and D. Mochly-Rosen
Pharmacological Inhibition of {epsilon}-Protein Kinase C Attenuates Cardiac Fibrosis and Dysfunction in Hypertension-Induced Heart Failure
Hypertension, June 1, 2008; 51(6): 1565 - 1569.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. H. Korzick, J. C. Kostyak, J. C. Hunter, and K. W. Saupe
Local delivery of PKC{varepsilon}-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2056 - H2063.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
I. Khaliulin, S. J. Clarke, H. Lin, J. Parker, M.-S. Suleiman, and A. P. Halestrap
Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore
J. Physiol., June 15, 2007; 581(3): 1147 - 1161.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. E. Anderson
Multiple downstream proarrhythmic targets for calmodulin kinase II: Moving beyond an ion channel-centric focus
Cardiovasc Res, March 1, 2007; 73(4): 657 - 666.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Ikeno, K. Inagaki, M. Rezaee, and D. Mochly-Rosen
Impaired perfusion after myocardial infarction is due to reperfusion-induced {delta}PKC-mediated myocardial damage
Cardiovasc Res, March 1, 2007; 73(4): 699 - 709.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. A. Apple, J. E. McLean, C. E. Squires, B. Schaeffer, J. A. Sample, R. L. Murphy, A. M. Deschamps, A. H. Leonardi, C. M. Allen, J. W. Hendrick, et al.
Differential Effects of Protein Kinase C Isoform Activation in Endothelin-Mediated Myocyte Contractile Dysfunction With Cardioplegic Arrest and Reperfusion
Ann. Thorac. Surg., August 1, 2006; 82(2): 664 - 671.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. D. T. Costa, R. Jakob, C. L. Costa, K. Andrukhiv, I. C. West, and K. D. Garlid
The Mechanism by Which the Mitochondrial ATP-sensitive K+ Channel Opening and H2O2 Inhibit the Mitochondrial Permeability Transition
J. Biol. Chem., July 28, 2006; 281(30): 20801 - 20808.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Mukherjee, K. A. Apple, C. E. Squires, B. S. Kaplan, J. E. McLean, S. M. Saunders, R. E. Stroud, and F. G. Spinale
Protein Kinase C Isoform Activation and Endothelin-1 Mediated Defects in Myocyte Contractility After Cardioplegic Arrest and Reperfusion
Circulation, July 4, 2006; 114(1_suppl): I-308 - I-313.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Z.-Q. Zhao and J. Vinten-Johansen
Postconditioning: Reduction of reperfusion-induced injury
Cardiovasc Res, May 1, 2006; 70(2): 200 - 211.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Inagaki, E. Churchill, and D. Mochly-Rosen
Epsilon protein kinase C as a potential therapeutic target for the ischemic heart
Cardiovasc Res, May 1, 2006; 70(2): 222 - 230.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Yamamura, C. Steenbergen, and E. Murphy
Protein kinase C and preconditioning: role of the sarcoplasmic reticulum
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2484 - H2490.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Bright and D. Mochly-Rosen
The Role of Protein Kinase C in Cerebral Ischemic and Reperfusion Injury
Stroke, December 1, 2005; 36(12): 2781 - 2790.
[Abstract] [Full Text] [PDF]